Disulfiram - Ora Bio

Drug Profile

Disulfiram - Ora Bio

Alternative Names: ORA-101; ORA-102

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer Ora Bio
  • Class Antineoplastics; Eye disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Age-related macular degeneration; Non-small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Aug 2015 No recent reports of development identified - Phase-II for Age-related macular degeneration (Combination therapy) in Israel (PO)
  • 06 Aug 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy) in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top